JP2024533356A5 - - Google Patents
Info
- Publication number
- JP2024533356A5 JP2024533356A5 JP2024515317A JP2024515317A JP2024533356A5 JP 2024533356 A5 JP2024533356 A5 JP 2024533356A5 JP 2024515317 A JP2024515317 A JP 2024515317A JP 2024515317 A JP2024515317 A JP 2024515317A JP 2024533356 A5 JP2024533356 A5 JP 2024533356A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- optionally substituted
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111085308 | 2021-09-16 | ||
| CN202111085308.7 | 2021-09-16 | ||
| PCT/CN2022/119214 WO2023041006A1 (zh) | 2021-09-16 | 2022-09-16 | 抗her3抗体药物偶联物及其组合物和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533356A JP2024533356A (ja) | 2024-09-12 |
| JP2024533356A5 true JP2024533356A5 (enExample) | 2025-10-02 |
Family
ID=85602455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024515317A Pending JP2024533356A (ja) | 2021-09-16 | 2022-09-16 | 抗ｈｅｒ３抗体薬物複合体及びその組成物並びに用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250018052A1 (enExample) |
| EP (1) | EP4389153A4 (enExample) |
| JP (1) | JP2024533356A (enExample) |
| KR (1) | KR20240056587A (enExample) |
| CN (3) | CN115957339A (enExample) |
| AU (1) | AU2022345316A1 (enExample) |
| CA (1) | CA3231491A1 (enExample) |
| IL (1) | IL311324A (enExample) |
| MX (1) | MX2024003025A (enExample) |
| TW (1) | TW202327661A (enExample) |
| WO (2) | WO2023041007A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024263367A1 (en) * | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| WO2024235135A1 (zh) * | 2023-05-12 | 2024-11-21 | 四川科伦博泰生物医药股份有限公司 | 大环化合物及其制备方法和用途 |
| WO2024235131A1 (zh) * | 2023-05-12 | 2024-11-21 | 四川科伦博泰生物医药股份有限公司 | 大环类药物偶联物及其制备方法和用途 |
| JPWO2024248123A1 (enExample) | 2023-06-02 | 2024-12-05 | ||
| EP4725969A1 (en) * | 2023-06-09 | 2026-04-15 | Latticon (Suzhou) Biopharmaceuticals Co., Ltd. | Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof |
| CN116444672B (zh) * | 2023-06-13 | 2023-11-03 | 上海偌妥生物科技有限公司 | 人表皮生长因子3的抗体、其制备方法及其应用 |
| WO2025092965A1 (zh) * | 2023-11-03 | 2025-05-08 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物的制备方法 |
| CN119925630A (zh) * | 2023-11-03 | 2025-05-06 | 正大天晴药业集团南京顺欣制药有限公司 | 抗体药物偶联物的制备方法 |
| CN117257977A (zh) * | 2023-11-07 | 2023-12-22 | 正大天晴药业集团南京顺欣制药有限公司 | 用于制备抗体药物偶联物的方法 |
| WO2026114362A1 (zh) * | 2024-11-29 | 2026-06-04 | 正大天晴药业集团股份有限公司 | 抗体-偶联物、其制备方法及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201901057UA (en) | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| MY199595A (en) * | 2016-03-02 | 2023-11-08 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| CN109422811A (zh) | 2017-08-29 | 2019-03-05 | 信达生物制药(苏州)有限公司 | 抗cd47抗体及其用途 |
| CR20250325A (es) * | 2018-04-13 | 2025-08-29 | Genentech Inc | Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550) |
| WO2020059772A1 (ja) * | 2018-09-20 | 2020-03-26 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
| CN111116745B (zh) * | 2018-11-01 | 2022-10-14 | 上海新理念生物医药科技有限公司 | 抗CD79b抗体、其药物偶联物及其应用 |
| KR102793948B1 (ko) * | 2019-08-07 | 2025-04-11 | 맙플렉스 인터내셔널 컴퍼니 리미티드 | 항체-약물 접합체 및 이의 용도 |
| WO2021090062A1 (en) * | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
| CA3164797A1 (en) * | 2019-12-23 | 2021-07-01 | Eisai R&D Management Co., Ltd. | Method of producing eribulin based antibody-drug conjugate |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| EP4190812A4 (en) * | 2020-07-27 | 2024-09-04 | Tuojie Biotech (Shanghai) Co., Ltd. | ANTI-CD79B ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS PHARMACEUTICAL USE |
| EP4768463A2 (en) | 2020-08-13 | 2026-07-01 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibody drug conjugate |
| AU2021381419A1 (en) * | 2020-11-20 | 2023-06-29 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Modified egfr antibody with reduced affinity, drug conjugate, and use thereof |
| WO2022104697A1 (en) * | 2020-11-20 | 2022-05-27 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. | Modified egfr antibody with reduced affinity |
-
2022
- 2022-09-16 IL IL311324A patent/IL311324A/en unknown
- 2022-09-16 CN CN202211126252.XA patent/CN115957339A/zh active Pending
- 2022-09-16 WO PCT/CN2022/119215 patent/WO2023041007A1/zh not_active Ceased
- 2022-09-16 CA CA3231491A patent/CA3231491A1/en active Pending
- 2022-09-16 CN CN202280049990.0A patent/CN117677400A/zh active Pending
- 2022-09-16 TW TW111135142A patent/TW202327661A/zh unknown
- 2022-09-16 US US18/690,483 patent/US20250018052A1/en active Pending
- 2022-09-16 KR KR1020247011779A patent/KR20240056587A/ko active Pending
- 2022-09-16 EP EP22869373.5A patent/EP4389153A4/en active Pending
- 2022-09-16 JP JP2024515317A patent/JP2024533356A/ja active Pending
- 2022-09-16 AU AU2022345316A patent/AU2022345316A1/en active Pending
- 2022-09-16 CN CN202280049991.5A patent/CN117642186A/zh active Pending
- 2022-09-16 WO PCT/CN2022/119214 patent/WO2023041006A1/zh not_active Ceased
- 2022-09-16 MX MX2024003025A patent/MX2024003025A/es unknown